文献速递产科母胎医学

妊娠期寨卡病毒感染的检测:应对新发疫情的关键概念

Testing for Zika virus infection in pregnancy: key concepts to deal with an emerging epidemic.
PubMed 文献 · Am J Obstet Gynecol · 2017-01-23

寨卡病毒是黄病毒科蚊媒虫媒病毒,2013年起在美洲50国流行,2015年10月巴西报告其与胎儿小头畸形等不良结局的因果关联。仅1/4-5感染者有症状,症状筛查无效;该专家综述讨论实验室与超声筛查诊断的局限性及替代神经超声方法。

要点

  • 寨卡病毒感染孕妇仅1/4-5出现症状,症状报告无法用于风险评估。
  • IgM血清学受暴露时间难以估计及与其他黄病毒交叉反应限制。
  • 超声仅依赖小头畸形检测有局限,可采用替代神经超声方法。

核心结论

  • 寨卡病毒感染多数无症状,临床症状报告不是评估感染相对风险的有效筛查工具。
  • 需开发并实施快速、敏感、特异的筛查与诊断检测,用于病毒检测和暴露时间估计。
  • 分子与超声筛查诊断先天性寨卡病毒感染存在多项持续障碍。

研究设计与样本

  • 专家综述(评论),讨论筛查与诊断考量,基于当前产科实践现实及基础免疫学与病毒学。
  • 复习近期基于暴露孕期的先天性寨卡病毒畸形风险流行病学数据,并与此前显示寨卡病毒在胎盘和胎儿组织中复制的数据并列考虑。

主要发现

  • 寨卡病毒为黄病毒科(Flaviviridae)伊蚊属(Aedes)蚊媒虫媒病毒。
  • 2013年5月前在南美洲首次报告疫情,现已扩散至美洲50个国家。
  • 2015年10月巴西受灾地区报告寨卡病毒与小头畸形、脑和眼畸形及胎儿丢失的因果关联。
  • 感染者中仅1/4-5出现症状,症状可包括发热、头痛、关节痛、肌痛和斑丘疹。
  • 妊娠期原发暴露后数周至数月持续存在病毒血症和病毒尿症。

关键数值与推荐

  • 居住于流行区女性暴露时间难以估计,限制IgM血清学可解释性。
  • IgM血清学与其他地方性黄病毒(如登革热)交叉反应。
  • 胎儿脑畸形和异常可先于超声检测到小头畸形出现。

临床怎么用

  • 专家综述为疑似寨卡病毒感染时的产科医生、母胎医学专家、助产士、患者及家庭提供信息。
  • 综述实验室检测方法以探查病毒存在和免疫反应。
  • 对疑似暴露于寨卡病毒的胎儿进行基于超声的评估,尤其关注中枢神经系统。
  • 识别准备开发的领域。

局限性

  • 居住于流行区女性暴露时间难以估计,限制IgM血清学可解释性。
  • IgM血清学与其他地方性黄病毒(如登革热)交叉反应。
  • 妊娠期原发暴露后数周至数月持续病毒血症和病毒尿症。
  • 胎儿脑畸形和异常可先于超声检测到小头畸形出现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Zika virus is an emerging mosquito-borne (Aedes genus) arbovirus of the Flaviviridae family. Following epidemics in Micronesia and French Polynesia during the past decade, more recent Zika virus infection outbreaks were first reported in South America as early as May 2013 and spread to now 50 countries throughout the Americas. Although no other flavivirus has previously been known to cause major fetal malformations following perinatal infection, reports of a causal link between Zika virus and microcephaly, brain and ocular malformations, and fetal loss emerged from hard-hit regions of Brazil by October 2015. Among the minority of infected women with symptoms, clinical manifestations of Zika virus infection may include fever, headache, arthralgia, myalgia, and maculopapular rash; however, only 1 of every 4-5 people who are infected have any symptoms. Thus, clinical symptom reporting is an ineffective screening tool for the relative risk assessment of Zika virus infection in the majority of patients. As previously occurred with other largely asymptomatic viral infections posing perinatal transmission risk (such as HIV or cytomegalovirus), we must develop and implement rapid, sensitive, and specific screening and diagnostic testing for both viral detection and estimation of timing of exposure. Unfortunately, despite an unprecedented surge in attempts to rapidly advance perinatal clinical testing for a previously obscure arbovirus, there are several ongoing hindrances to molecular- and sonographic-based screening and diagnosis of congenital Zika virus infection. These include the following: (1) difficulty in estimating the timing of exposure for women living in endemic areas and thus limited interpretability of immunoglobulin M serologies; (2) cross-reaction of immunoglobulin serologies with other endemic flaviruses, such as dengue; (3) persistent viremia and viruria in pregnancy weeks to months after primary exposure; and (4) fetal brain malformations and anomalies preceding the sonographic detection of microcephaly. In this commentary, we discuss screening and diagnostic considerations that are grounded not only in the realities of current obstetrical practice in a largely global population but also in basic immunology and virology. We review recent epidemiological data pertaining to the risk of congenital Zika virus malformations based on trimester of exposure and consider side by side with emerging data demonstrating replication of Zika virus in placental and fetal tissue throughout gestation. We discuss limitations to ultrasound based strategies that rely largely or solely on the detection of microcephaly and provide alternative neurosonographic approaches for the detection of malformations that may precede or occur independent of a small head circumference. This expert review provides information that is of value for the following: (1) obstetrician, maternal-fetal medicine specialist, midwife, patient, and family in cases of suspected Zika virus infection; (2) review of the methodology for laboratory testing to explore the presence of the virus and the immune response; (3) ultrasound-based assessment of the fetus suspected to be exposed to Zika virus with particular emphasis on the central nervous system; and (4) identification of areas ready for development.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Eppes C, Rac M, Dunn J, et al. Testing for Zika virus infection in pregnancy: key concepts to deal with an emerging epidemic. Am J Obstet Gynecol. 2017. PMID: 28126366. doi:10.1016/j.ajog.2017.01.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。